Table 1 Correlations between AUF1 expression and clinicopathological characteristics in breast cancer patients
Parameter | Total (n = 338) | AUF1 in stromal fibroblasts | P value | |
|---|---|---|---|---|
(%) | < 10 | > 10 | ||
Age | ||||
< 50 years | 247 (73.08) | 182 (53.85) | 65 (19.23) | 0.5442 |
> 50 years | 91 (26.92) | 70 (20.71) | 21 (6.21) | |
Tumor size | ||||
T2 | 78 (23.93) | 57 (15.48) | 21 (6.44) | |
T3 | 116 (35.58) | 90 (27.61) | 26 (7.98) | 0.5799 |
T4 | 132 (40.49) | 95 (29.14) | 37 (11.35) | |
Stage | ||||
II B | 85 (26.07) | 62 (19.02) | 23 (7.06) | 0.6988 |
III A | 100 (30.67) | 77 (23.62) | 23 (7.06) | |
III B | 141 (43.25) | 102 (31.29) | 39 (11.96) | |
Ki-67 index | 335 | |||
0 | 313 (93.43) | 232 (69.25) | 81 (24.18) | 0.5924 |
< 15 | 3 (0.90) | 3 (0.90) | 0 (0) | |
> 15 | 19 (5.76) | 14 (4.18) | 5 (1.49) | |
Recurrence | ||||
No | 201 (59.47) | 153 (45.27) | 48 (14.20) | 0.4242 |
Yes | 137 (40.53) | 99 (29.29) | 38 (11.24) | |
Grade | ||||
Gl/well diff | 5 (1.48) | 5 (1.48) | 0 (0) | |
G2/moderately diff | 169 (50.00) | 134 (39.64) | 35 (10.36) | 0.0021 |
G3/poorly diff | 144 (42.60) | 94 (27.81) | 50 (14.79) | |
Gx/unknown | 20 (5.92) | 19 (5.62) | 1 (0.30) | |
Lymph nodes | ||||
N0 | 36 (10.65) | 28 (8.28) | 8 (2.37) | 0.5782 |
N1 | 182 (53.85) | 139 (41.12) | 43 (12.72) | |
N2 | 87 (25.74) | 60 (17.75) | 27 (7.99) | |
N3 | 33 (9.76) | 25 (7.40) | 8 (2.37) | |
Progression | ||||
No | 223 (65.98) | 170 (50.30) | 53 (15.68) | 0.3243 |
Yes | 115 (34.02) | 82 (24.26) | 33 (9.76) | |
Survival status | ||||
Alive | 265 (78.40) | 203 (60.06) | 62 (18.34) | 0.0096 |
Dead | 73 (21.60) | 49 (14.50) | 24 (7.10) | |
Duration of clinical follow-up | 7.8215 | 6.0165 | ||
Parameter | Total (n = 337) | AUF1 in cancer cells | P value | |
|---|---|---|---|---|
(%) | < 10% | > 10% | ||
Age | ||||
< 50 years | 246 (73.00) | 145 (43.03) | 101 (29.97) | 0.0550 |
> 50 years | 91 (27.00) | 43 (12.76) | 48 (14.24) | |
Tumor size | ||||
T2 | 78 (23.93) | 40 (12.27) | 38 (11.66) | |
T3 | 116 (35.58) | 67 (20.55) | 49 (15.03) | 0.6731 |
T4 | 132 (40.49) | 73 (22.39) | 132 (40.49) | |
Recurrence | ||||
No | 200 (59.35) | 108 (32.05) | 92 (27.30) | 0.4250 |
Yes | 137 (40.65) | 80 (23.74) | 57 (16.91) | |
Grade | ||||
G1/well diff | 5 (1.48) | 4(1.19) | 1 (0.30) | |
G2/moderately diff | 169 (50.15) | 98 (29.08) | 71 (21.07) | 0.0295 |
G3/poorly diff | 143 (42.43) | 70 (20.77) | 73 (21.66) | |
Gx/unknown | 20 (5.93) | 16 (4.75) | 4 (1.19) | |
Stage | ||||
II B | 85 (26.15) | 46 (14.15) | 39 (12.00) | 0.9205 |
III A | 99 (30.46) | 53 (16.31) | 46 (14.15) | |
III B | 141 (43.38) | 79 (24.31) | 62 (19.08) | |
Lymph nodes | ||||
N0 | 36 (10.68) | 14 (5.04) | 19 (5.64) | |
N1 | 182 (54.01) | 107 (31.75) | 75 (22.26) | 0.2923 |
N2 | 86 (25.52) | 43 (12.76) | 43 (12.76) | |
N3 | 33 (9.79) | 21 (6.23) | 12 (3.56) | |
Progression | ||||
No | 222 (65.88) | 116 (34.42) | 106 (31.45) | 0.0695 |
Yes | 115 (34.12) | 72 (21.36) | 43 (12.76) | |
Survival status | ||||
Alive | 264 (78.34) | 145 (43.03) | 119 (35.31) | 0.5445 |
Dead | 73 (21.66) | 43 (12.76) | 30 (8.90) | |
Duration of clinical follow-up | 8.0190 | 6.5356 | ||